Incyte (INCY) stock is in focus after the US FDA approved once daily Jakafi XR, along with positive Phase 3 Opzelura data in atopic dermatitis and orphan drug designation for a pancreatic cancer therapy.

Despite a 1-day share price decline of 2.08% to about $97.77, Incyte’s 63.69% 1-year total shareholder return and recent FDA wins suggest momentum has been building around its pipeline and diversification efforts.

If recent oncology and dermatology updates have your attention, this could be a good moment to see what else is moving in healthcare related AI. Check out 35 healthcare AI stocks

With shares up 63.69% over the past year and trading around $97.77, recent drug approvals and pipeline updates are already in the spotlight. The key question is whether Incyte is still underappreciated or if markets are already pricing in what comes next.

Most Popular Narrative: 9.9% Undervalued

With Incyte’s last close at $97.77 and the most followed fair value estimate at $108.50, the current price sits below what this narrative implies.

The upcoming launches and label expansions of therapies like Opzelura, povorcitinib, and Niktimvo in high-value indications such as atopic dermatitis, vitiligo, hidradenitis suppurativa, and GVHD, along with a late-stage pipeline of targeted drugs, position Incyte to benefit from heightened demand for advanced immunology and oncology treatments as global populations age. This likely supports sustained revenue growth and future earnings. Recent advances in precision medicine, exemplified by early clinical data for mutant CALR antibody 989 and collaboration for mutation-specific diagnostics, align with accelerating adoption of targeted therapies and may expand addressable markets and support margin expansion.

Curious what kind of revenue path, margin profile, and future earnings multiple sit behind that $108.50 figure? The narrative leans on specific growth, profitability and valuation assumptions that could reshape how you think about this stock’s next chapter.

Result: Fair Value of $108.50 (UNDERVALUED)

However, this storyline meets real tension around Jakafi patent risk and the possibility that higher R&D and SG&A spending erodes margins if newer drugs fall short.

Another View: Cash Flows Point The Other Way

That 9.9% “undervalued” story from the $108.50 fair value sits uncomfortably next to our DCF model, which puts Incyte’s future cash flow value at $50.78. With the stock at $97.77, this approach flags the shares as expensive rather than cheap and raises very different questions about risk and upside.

For investors, the gap between a cash flow driven estimate of $50.78 and a narrative fair value of $108.50 is less about choosing a side and more about deciding which set of assumptions feels more realistic for revenue, margins, and terminal value. Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Incyte for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 51 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Mixed signals on value and risk so far. If this has you on the fence, take a moment to review both sides of the thesis and weigh the 2 key rewards and 1 important warning sign.

Looking for more investment ideas?

If Incyte has you thinking more broadly about your portfolio, this can be a good time to scan for fresh opportunities before the market moves on without you.

• Target potential mispricings by reviewing companies highlighted in the 51 high quality undervalued stocks and see which stocks might offer more appealing entry points.
• Prioritize resilience by focusing on companies in the 72 resilient stocks with low risk scores and see which businesses score well on stability and downside protection.
• Spot underfollowed opportunities early by checking the screener containing 23 high quality undiscovered gems and see which stocks could be flying under most investors' radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.